Subscribe to Novo Nordisk Perspectives



When you subscribe we ask for your e-mail address.

How we use this information

 



About Perspectives

Perspectives will take you behind the scenes at Novo Nordisk and showcase the views of our management, partners and the people we serve around the world.

When you subscribe, you’ll receive an email when new articles are published – on average once or twice per month.

See all featured articles here


You also get Perspectives when you follow Novo Nordisk
 


 

The pursuit of oral insulin

Novo Nordisk Chief science officer Mads Krogsgaard Thomsen reflects on the past, present and future of insulin in a tablet.

Oral insulin remains the ‘Holy Grail’ of diabetes

 

 

It's time we changed the conversation about obesity

President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen on why the definition of obesity is just the beginning of a broader, more significant discussion.

Change of the obesity conversation

 

It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity
It’s time we changed the conversation about obesity

 

Why we must do more to tackle chronic disease in humanitarian crises

CEO, Lars Fruergaard Jørgensen, reflects on the challenge of providing access to care among vulnerable populations displaced by conflict

Driving access to care for refugees